Intellia Therapeutics
NTLA
156 hedge funds and large institutions have $789M invested in Intellia Therapeutics in 2018 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 55 increasing their positions, 29 reducing their positions, and 13 closing their positions.
208% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 13
90% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 29
42% more capital invested
Capital invested by funds: $557M → $789M (+$232M)
20% more funds holding
Funds holding: 130 → 156 (+26)
16% more call options, than puts
Call options by funds: $7.78M | Put options by funds: $6.72M
4.65% more ownership
Funds ownership: 62.31% → 66.97% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$22.1M |
| 3 |
BlackRock
New York
|
+$20.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.62M |
| 5 |
Morgan Stanley
New York
|
+$7.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.6M |
| 2 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$10.7M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$6.95M |
| 4 |
O
OrbiMed
New York
|
-$5.74M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.66M |
NTLA Hedge Fund Activity: Q2 2018 in Review
156 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2018, worth a combined $789M — up 42% from $557M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new NTLA positions and 13 closed out — a net gain of 27 holders — while 55 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $28M. The largest seller was Fidelity Investments, cutting an estimated $29.6M.
- 156 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2018, up from 130 in Q1 2018.
- Funds reported $789M of Intellia Therapeutics stock for Q2 2018, up 42% quarter-over-quarter.
- 40 funds opened new Intellia Therapeutics positions in Q2 2018 and 13 closed out, a net change of +27 holders.
- The largest Intellia Therapeutics buyer in Q2 2018 was State Street, an estimated $28M added.
- The largest Intellia Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $29.6M sold.
Based on aggregated 13F filings for Q2 2018.